Global fill/finish Acquired by Emergent BioSolutions, the Cangene bioPharma contract manufacturing site in Baltimore specializes in aseptic fill/finish for liquids and lyophilized products, serving clients across more than 50 countries. Opportunity: target pharma and biotech firms seeking reliable, compliant fill/finish capacity and cross-border distribution.

Regulatory track Facility is inspected and approved by major regulatory bodies in US, EU, Brazil, Middle East and Japan, indicating strong compliance capabilities. Opportunity: engage sponsors needing validated, multi-region manufacturing footprints to accelerate global clinical programs and launches.

Clinical to commercial With a history of supporting over 185 clinical products and currently producing 24 commercial products, the site has proven capability to scale from development to commercial scale. Opportunity: pitch end-to-end CDMO services including process optimization, scale-up support, and continuous manufacturing readiness.

Global distribution Manufactured products are distributed to more than 50 countries, underscoring an established logistics and regulatory-ready framework. Opportunity: present international supply chain solutions, packaging, and labeling services tailored to diverse regional requirements.

Growth alignment As part of Emergent BioSolutions, the site benefits from a broader portfolio and potential demand from public health programs and government contracts. Opportunity: pursue collaborations or contract opportunities with government-funded initiatives, regional health programs, and emergency preparedness projects.